Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective International Multicenter Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of Mexidol® in Sequential Treatment of Patients in the Acute and Early Recovery Periods of Ischemic Stroke

NCT06437626 is registered in ClinicalTrials.gov with Pharmasoft as lead sponsor.

NCT NCT06437626
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06437626 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective International Multicenter Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of Mexidol® in Sequential Treatment of Patients in the Acute and Early Recovery Periods of Ischemic Stroke
Lead sponsor
Pharmasoft
Phase
Phase 3
Overall status
Completed
Start date
November 18, 2019
Completion date
August 18, 2023
Enrollment
304 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

ischemic stroke